This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, G. Articles by Thompson, T. C. Search for Related Content PubMed PubMed Citation Articles by Yang, G. Articles by Thompson, T. C.

Elevated Caveolin-1 Levels in African-American versus White-American Prostate Cancer¹

Departments of Urology [G. Y., J. A., T. M. W., T. C. T.], Pathology [M. I., T. M. W.], Molecular and Cellular Biology [T. C. T.], and Radiology [T. C. T.], Baylor College of Medicine, Houston, Texas 77030

Clinical studies suggest that African-American (AA) prostate cancer patients manifest a more aggressive form of the disease compared with white prostate cancer patients. However, the biological underpinnings of this potential difference remain unresolved. To address this issue, we used specific quantitative immunostaining protocols to determine whether a panel of biomarkers related to apoptosis including caveolin-1, bcl-2, p53, and c-myc were differentially expressed in AA versus white prostate cancer patients with similar clinical and pathological characteristics. We further attempted to correlate biomarker positivity with proliferation-related markers including Ki-67 labeling index and apoptotic index. Interestingly, our results indicated that only the incidence of caveolin-1 staining was significantly different between these two ethnic/racial groups of prostate cancer patients. The incidence of caveolin-1 staining in white patients was 17% compared with 39% in AA patients (P = 0.0048; Fisher’s exact test). In addition, the percentage of caveolin-1-positive prostate cancer cells was also higher in moderately differentiated (Gleason score 6) prostate cancer patients in AA versus whites. Because caveolin-1 has been shown previously to demonstrate antiapoptotic activities in prostate cancer cells, our results suggest that differences in caveolin-1 expression may in part underlie the apparent differences in the clinical virulence of this disease in AA versus white prostate cancer patients.

This article has been cited by other articles:

				H. H. Patel, S. Zhang, F. Murray, R. Y. S. Suda, B. P. Head, U. Yokoyama, J. S. Swaney, I. R. Niesman, R. T. Schermuly, S. S. Pullamsetti, et al. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension FASEB J, September 1, 2007; 21(11): 2970 - 2979. [Abstract] [Full Text] [PDF]

				R. A. Siddiqui, K. A. Harvey, G. P. Zaloga, and W. Stillwell Modulation of Lipid Rafts by {Omega}-3 Fatty Acids in Inflammation and Cancer: Implications for Use of Lipids During Nutrition Support Nutr Clin Pract, February 1, 2007; 22(1): 74 - 88. [Abstract] [Full Text] [PDF]

				S. A. Tahir, A. Frolov, T. G. Hayes, M. P. Mims, B. J. Miles, S. P. Lerner, T. M. Wheeler, G. Ayala, T. C. Thompson, and D. Kadmon Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort. Clin. Cancer Res., August 15, 2006; 12(16): 4872 - 4875. [Abstract] [Full Text] [PDF]

				G. E. Ayala, H. Dai, S. A. Tahir, R. Li, T. Timme, M. Ittmann, A. Frolov, T. M. Wheeler, D. Rowley, and T. C. Thompson Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res., May 15, 2006; 66(10): 5159 - 5164. [Abstract] [Full Text] [PDF]

				J. Kim, R. M. Adam, K. R. Solomon, and M. R. Freeman Involvement of Cholesterol-Rich Lipid Rafts in Interleukin-6-Induced Neuroendocrine Differentiation of LNCaP Prostate Cancer Cells Endocrinology, February 1, 2004; 145(2): 613 - 619. [Abstract] [Full Text] [PDF]

				S. A. Tahir, C. Ren, T. L. Timme, Y. Gdor, R. Hoogeveen, J. D. Morrisett, A. Frolov, G. Ayala, T. M. Wheeler, and T. C. Thompson Development of an Immunoassay for Serum Caveolin-1: A Novel Biomarker for Prostate Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3653 - 3659. [Abstract] [Full Text] [PDF]

				G. Cao, G. Yang, T. L. Timme, T. Saika, L. D. Truong, T. Satoh, A. Goltsov, S. H. Park, T. Men, N. Kusaka, et al. Disruption of the Caveolin-1 Gene Impairs Renal Calcium Reabsorption and Leads to Hypercalciuria and Urolithiasis Am. J. Pathol., April 1, 2003; 162(4): 1241 - 1248. [Abstract] [Full Text] [PDF]

				L. Zhuang, J. Lin, M. L. Lu, K. R. Solomon, and M. R. Freeman Cholesterol-rich Lipid Rafts Mediate Akt-regulated Survival in Prostate Cancer Cells Cancer Res., April 1, 2002; 62(8): 2227 - 2231. [Abstract] [Full Text] [PDF]

				C. Pramudji, S. Shimura, S. Ebara, G. Yang, J. Wang, C. Ren, Y. Yuan, S. A. Tahir, T. L. Timme, and T. C. Thompson In Situ Prostate Cancer Gene Therapy Using a Novel Adenoviral Vector Regulated by the Caveolin-1 Promoter Clin. Cancer Res., December 1, 2001; 7(12): 4272 - 4279. [Abstract] [Full Text] [PDF]